Summit Therapeutics Inc.(SMMT)
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest News & Analysis
Summit Therapeutics (SMMT): Clinical Trials, Analyst Ratings, and Outlook
Analysis of Summit Therapeutics (SMMT): Clinical trials, analyst ratings, market outlook, inducement grants, and macroeconomic factors impacting investment potential.
Summit Therapeutics (SMMT): Pipeline Progress & Strategic Analysis
Analysis of Summit Therapeutics (SMMT): Analyst optimism, pipeline progress, strategic collaborations, and market volatility. Key developments and financial insights.
Summit Therapeutics (SMMT): Leadership, Pfizer Deal, Ivonescimab
Analysis of Summit Therapeutics (SMMT): leadership changes, Pfizer collaboration, and ivonescimab's potential in NSCLC treatment.
SMMT: Summit Therapeutics' Ivonescimab & Pfizer Collaboration
Analysis of Summit Therapeutics' collaboration with Pfizer, focusing on ivonescimab's potential in NSCLC treatment and financial implications for investors.
Summit Therapeutics (SMMT): Q4 Loss, Pfizer Deal, and Ivonescimab's Promise
Summit Therapeutics faces Q4 loss but a Pfizer collaboration boosts ivonescimab's potential. This analysis covers financials, market landscape, and future prospects.
Summit Therapeutics: Q4 Results and Pfizer Collaboration – A Game Changer?
Summit Therapeutics balances Q4 results with a Pfizer collaboration, focusing on Ivonescimab's potential. Mid-2025 NSCLC data is crucial for its future.
Summit Therapeutics: Q4 Results, Pfizer Collaboration, Ivonescimab
Summit Therapeutics navigates market volatility with Q4 results, a Pfizer collaboration, and ivonescimab's potential. A comprehensive analysis of recent developments.
Summit Therapeutics: Ivonescimab's NSCLC Trial Results - A Game Changer?
A deep dive into Summit Therapeutics' Ivonescimab, its clinical trial results, financial outlook, and potential impact on the NSCLC treatment landscape.